<DOC>
	<DOC>NCT01153698</DOC>
	<brief_summary>an open, prospective, observational study to collect data on safety (major bleeding events) and efficacy (symptomatic venous thromboembolism(VTE)) of a switch from Enoxaparin to dabigatran etexilate in patients with total knee replacement (TKR) and total hip replacement (THR)</brief_summary>
	<brief_title>Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criteria: patients age 18 years or above undergoing elective total hip or knee replacement surgery Exclusion criteria: according to the label recommendation for Pradaxa 220 mg QD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>